The latest generation of diabetes medication is currently in great demand as it can also cause weight loss. Due to high demand, falsifications are increasingly appearing on the market. At the end of last week, Freiburg im Breisgau Regional Council announced that falsified packs of manufacturer Novo Nordisk’s Ozempic® pens are currently in circulation in Germany. Their use poses a high risk to health.
The Regional Council in Freiburg im Breisgau, Germany, has warned against the use of counterfeit Ozempic® pens
09.10.2023
Falsified products should under no circumstances be used, and should be taken to a pharmacy. Swissmedic asks that any suspicious cases be reported to medicrime@swissmedic.ch.
The original preparations from the manufacturer Novo Nordisk pose no risk. The originals differ clearly in appearance from the falsifications, as shown on the pictures of the original product and the falsification provided by the Freiburg im Breisgau Regional Council.
Swissmedic generally advises that only medications from officially authorised and monitored sales channels are of a high quality and safe to use. Furthermore, Ozempic® is not authorised for use in weight loss. It must therefore only be used under medical supervision.
See also
Swissmedic issues warning about falsified Ozempic pens
Hospitalisations following use of falsified Ozempic pens – Swissmedic advises against purchasing medicinal products online and from unreliable sources abroad